Vitro and PhosphoSolutions Collaborate to Study Stem Cell Proteomics

Vitro Diagnostics, Inc. (OTC BB: VODG), dba Vitro Biopharma, announced establishment of research collaboration with PhosphoSolutions, LLC (Aurora Colorado) to characterize intracellular signaling mechanisms involved with regulation of stem cell growth and differentiation. Vitro has previously developed 29 adult pancreatic stem cell lines and has developed methodologies to induce differentiation of functional human beta cells from these cell lines. PhosphoSolutions makes and supplies antibodies to medical researchers, specifically in cancer biology and neuroscience. PhosphoSolutions focuses on the generation of antibodies which can discriminate a target protein (antigen) based on its phosphorylation state. While phosphoproteins represent only 15-20% of all proteins, they regulate virtually every cellular function, including growth and differentiation. These phospho-specific antibodies can thus be used to assess the activity of a protein, not simply its level of expression. "We are pleased to be working with Vitro to apply our expertise and antibodies to study intracellular signaling pathways involved in the growth and differentiation of Vitro's stem cells," said Dr. Ron Lickteig, Ph.D., senior scientist at PhosphoSolutions.

Stem cells exhibit immortality through self-renewal properties that are typically activated in normal development. Early investigations by Vitro and PhosphoSolutions have provided evidence suggesting interaction between these key regulatory pathways through phosphorylation of a well-known protein, (GSK3-b(Beta)), supporting work recently completed by other researchers. The goals of the collaboration are to further investigate intracellular signaling mechanisms underlying stem cell self-renewal and those pathways involved with differentiation of stem cells into functional cells, including beta cells that synthesize and release insulin. These studies may advance the understanding of stem cell function and lead to new approaches to selectively activate the regenerative capacity of adult stem cells or to suppress "overactive signaling pathways" in stem cells thought to underlie growth of certain cancerous tumors.

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTC BB: VODG), http://www.vitrodiag.com, founded in 1986, is a biotechnology company that developed and manufactures the VITROCELL(TM) brand of human cell lines consisting of pituitary and pancreatic-derived cell lines and related products for various research and commercial applications. The Company also owns proprietary stem cell technology with potential application in the treatment of animal and human diabetes.

About PhosphoSolutions, Inc.

PhosphoSolutions, located in Aurora, Colorado, produces and markets phosphospecific antibodies to research institutes, universities and pharmaceutical companies throughout the world. Additionally, PhosphoSolutions is developing protein antibody microarrays containing its antibodies to meet researchers' need to assay multiple components of phosphorylation signaling pathways in a high throughput fashion. These arrays will greatly facilitate the development of the second generation of anti-cancer drugs such as Novartis' Gleevec that are targeted at phosphorylation signaling.

Safe Harbor Statement

Certain statements contained herein and subsequent oral statements made by and on behalf of the Company may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's Annual Report on Form 10-KSB for the fiscal year ended October 31, 2004 under the caption, "Risk Factors." Most these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Distributed by Market Wire